Creating and developing a logo for any pharmaceutical company is critical when building a business brand. The logo design has to communicate the right message to the right audience. It also needs to be direct and effective, and must express concisely what the company is trying to say to its audience. In other words, the logo needs to describe the essence of the business in simplest terms by the use of imagery. A weak or poor logo will, by association, give the wrong impression to the audience. The Cinnamon Agency understands this, and has had a wealth of experience working on logo development for some of the pharmaceutical industry’s major brands. Our aim is to deliver the best visual representation of the essence of our client’s business, so we work and communicate with our client throughout the whole development process, from the initial pencil drawing right through to the final client-approved logo.
The Cinnamon Agency, working in conjunction with Adelphi Communications, recently worked on a logo development for our client, Pfizer (Anti-infectives), to promote its new antifungal treatment Ecalta. Pfizer is one of the world’s leading pharmaceutical producers and is committed to shaping a society in which people live longer, healthier and more-productive lives.
Our brief, in conjunction with Adelphi Communications, was to develop a logo for our client, Pfizer (Anti-infectives) to promote and advertise its new antifungal treatment, Ecalta. Ecalta (anidulafungin) is the latest member of the echinocandin class of antifungals medicines, which are designed to prevent the production of glucan in the fungal cell wall, which leads to a loss of rigidity, causing the cell wall to breakdown. Unlike the majority of other antifungal classes, such as polyenes or azoles, Ecalta targets the cell membrane.
The new drug was approved in the UK in 2007 following a pivotal clinical trial which had clearly demonstrated its effectiveness in fighting serious Candida infections, which are potentially life-threatening in critical care patients, with successful treatment in 75.6% of patients compared with 60.2% of those given Pfizer’s Diflucan (fluconazole). Fungal infections like candidaemia can be fatal and have an estimated crude mortality rate of 38%.